Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 178, Issue 6, Pages 509-521Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2020.20030340
Keywords
-
Categories
Funding
- NIMH
- National Institute of Neurological Disease and Stroke (NINDS)
- National Institute onAging(NIA)
- Patient-CenteredOutcomesResearchInstitute
- Stanley Foundation
- J.B. Fuqua Foundation
- Minnesota's Discovery, Research, and InnoVation Economy (MnDRIVE) initiative
- Minnesota Medical Discovery Team on Addictions
- NIH
- Biohaven Pharmaceuticals
- Stanley Medical Research Institute
- NIMH [K23MH106683, R01MH118484]
- Cervel Neurotherapeutics
- NeoSync
- Neuronetics
- Soterix
Ask authors/readers for more resources
Schizophrenia is a complex neuropsychiatric syndrome with no objective biological markers available for diagnostic or treatment decisions. Neuroimaging is considered a promising tool for biomarker development in schizophrenia, as it can capture phenotypic variations in disease targets, validate new treatment targets, predict response, aid in therapy selection, and provide rationale for personalized treatments.
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological, and phenotypic profile. Currently, no objective biological measures-that is, biomarkers-are available to inform diagnostic or treatment decisions. Neuroimaging is well positioned for biomarker development in schizophrenia, as it may capture phenotypic variations inmolecular and cellular disease targets, or in brain circuits. These mechanistically based biomarkers may represent a direct measure of the pathophysiological underpinnings of the disease process and thus could serve as true intermediate or surrogate endpoints. Effective biomarkers could validate new treatment targets or pathways, predict response, aid in selection of patients for therapy, determine treatment regimens, and provide a rationale for personalized treatments. In this review, the authors discuss a range of mechanistically plausible neuroimaging biomarker candidates, including dopamine hyperactivity, N-methyl-D-aspartate receptor hypofunction, hippocampal hyperactivity, immune dysregulation, dysconnectivity, and cortical gray matter volume loss. They then focus on the putative neuroimaging biomarkers for disease risk, diagnosis, target engagement, and treatment response in schizophrenia. Finally, they highlight areas of unmet need and discuss strategies to advance biomarker development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available